Pharma - HealthQuill

The US regulator is initiating action to remove concentrated ingestible fluoride prescription drug products for children from the market, a move that drew ire from dental experts.

US plan to remove ingestible fluoride from children’s drugs draws ire

HQ Team May 14, 2025: The US regulator is initiating action to remove concentrated ingestible fluoride prescription drug products for children from the.

by HealthQuill
May 15, 2025
0 Comments

The US Food and Drug Administration (FDA) has granted an accelerated approval for AbbVie Inc.’s drug to treat a specific group of adult lung cancer patients who have tried other systemic treatments.

Drugs Health Pharma

AbbVie’s NSCLC lung cancer drug gets accelerated approval from FDA

HQ Team May 15, 2025: The US Food and Drug Administration (FDA) has granted an accelerated approval for AbbVie Inc.’s drug to treat.

by HealthQuill
May 15, 2025
0 Comments

Harvard University has amended its lawsuit against the US administration by saying that its researchers would lose another $450 million in grants from several agencies.

Health Medical Pharma

Harvard amends lawsuit as federal agencies threaten to cut short grants

HQ Team May 15, 2025: Harvard University has amended its lawsuit against the US administration by saying that its researchers would lose another.

by HealthQuill
May 15, 2025
0 Comments

Merck & Co. got approval from the US Food and Drug Administration for a pill to treat a rare type of tumour in adults and children aged above 12 years, according to a statement.

Drugs Health Pharma

Merck’s pill to treat rare type of tumour gets approval from US regulator

HQ Team May 15, 2025: Merck & Co. got approval from the US Food and Drug Administration for a pill to treat a.

by HealthQuill
May 15, 2025
0 Comments

Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor that may cure chronic pain without using opioids.

Drugs Health Pharma

Novo Nordisk, Septerna in $2.2b deal to develop oral molecules

HQ Team May 14, 2025: Novo Nordisk and Septerna, Inc., have inked a $2.2 billion global collaboration and licensing pact to develop oral.

by HealthQuill
May 14, 2025
0 Comments

GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2 billion in cash.

Drugs Health Pharma

GSK to buy Boston’s lead drug asset for liver disease for $2 billion in cash

HQ Team May 14, 2025: GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2.